Our team brings together proven leaders with diverse experiences and deep expertise across all aspects of a successful biotech company. We are united by a belief in the transformative potential of gene therapy and by our steadfast commitment to making a difference in the lives of children and families affected by rare disease.

member image alt text
Bobby Gaspar, M.D., Ph.D.
Chief Executive Officer
To me, leading Orchard is an opportunity to change medicine and change the lives of individuals with severe genetic diseases and their families. Through our hematopoietic stem cell platform, cutting-edge science and innovation, and well-executed clinical studies, we can deliver potentially curative therapies for patients. However, the success of our efforts also requires enabling meaningful access to therapy and building the necessary infrastructure across core pillars – regulatory science, manufacturing, diagnostic and commercial capabilities, and education and advocacy – to ultimately deliver on our mission to potentially transform lives.

Bobby is a world-renowned scientist and physician and accomplished strategic and organizational leader with more than 25 years of experience in medicine and biotechnology. As one of Orchard’s principal scientific founders, Bobby serves as chief executive officer of the company, and also sits on Orchard’s board of directors. Bobby has been a pioneer in gene therapy and the evolution of hematopoietic stem cell (HSC) technology – including some of the first studies in patients with severe combined immunodeficiency (SCID) – bringing it from some of the first studies in patients to potential regulatory approvals. His unparalleled expertise and deep relationships with key physicians and treatment centers around the world are integral to Orchard’s efforts to identify patients with metachromatic leukodystrophy (MLD) and other diseases through targeted disease education, early diagnosis and comprehensive newborn screening.

Bobby is a professor of pediatrics and immunology at the UCL Great Ormond Street Institute of Child Health and has led multiple clinical trials that have shown that gene therapy can successfully correct the genetic defect in immune deficiencies. He studied medicine and surgery at Kings College in London before completing his Ph.D. at the UCL Institute of Child Health.

member image alt text
John Cerio
Chief Human Resource Officer
We are building a highly collaborative culture with a deep understanding and appreciation of our diverse talents and collective strengths, and an abiding commitment to our mission to potentially transform the lives of families affected by rare disease.

John brings over 25 years of human resource (HR) leadership experience in the pharmaceutical and biotech industry building high growth, high performance, mission-driven and entrepreneurial companies. Most recently, John served as vice president of human resources and administration for Agenus, where he led the HR function through periods of rapid growth, transformation and global expansion. John played a key role in leading the acquisition and integration of 4-antibody AG and the build-out of the company’s R&D and technical operations capabilities responsible for generating and advancing an immuno-oncology portfolio of over a dozen clinical candidates. Prior to Agenus, John was vice president of global HR for PerkinElmer Life Sciences, during which time the company more than doubled in size and annual sales and significantly expanded its commercial business and operations in the U.S., Europe and APAC regions. Earlier in his career, he spent nearly 10 years with Bristol-Myers Squibb in a series of progressively responsible HR leadership roles including director of HR for corporate staff, director of organizational development for U.S. medicines and head of HR for the oncology and immunology division.

John earned his B.S. in industrial and labor relations from Cornell and his M.A. in organizational psychology from Columbia with a concentration in organizational development. He also completed the global leadership development program at the London Business School.

member image alt text
Anne Dupraz-Poiseau, Ph.D.
Chief Development Officer
We will always be confronted by obstacles in life. The important thing is being open to new routes to meet our goals and going beyond our limitations. This is what Orchard is working towards: developing the medicines of tomorrow, which might previously have been seen as impossible, but will potentially be standards of care in the future.

Anne has 25 years of experience tackling R&D, clinical and regulatory challenges for global development within medtech and biotech companies. Anne joined Orchard Therapeutics in 2016 to lead global regulatory strategy and devise innovative and expedited pathways for the development and the registration of Orchard’s HSC gene therapies. She built and manages an international, highly-trained and experienced regulatory team. Prior to joining Orchard Therapeutics, she was executive vice president at Voisin Consulting Life Sciences (VCLS), an international consulting firm highly experienced in orphan drug development. In her leadership role, Anne was actively involved in the design, preparation and management of a high number of successful regulatory submissions at all stages of product development. Anne had a pioneering role in the field of advanced therapies and managed over 50 different tissue, cell and gene-based therapy development programs. Over the years, Anne has established strong communication links with regulators, including the Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the European Member States’ medicine agencies. Bringing together scientific and regulatory expertise in the Advanced Therapies Medicinal Products (ATMPs) area, Anne actively participated in the elaboration of the European ATMP Regulation through industry associations and worked closely with the EMA on related guidelines. Before joining VCLS, Anne co-founded the regulatory consulting firm Meditest International. Anne began her career as a research & development project manager for Medtronic Sofamor-Danek.

Anne earned a joint Ph.D. in biomaterials and artificial organs from the University of Dental Surgery in Nantes, France, the Free University of Berlin, Germany, and the University of Medicine of Leiden, Netherlands, working on the development and evaluation of drug-device combination products aimed at bone substitution.

member image alt text
Nicoletta Loggia, Ph.D.
Chief Technical Officer

Nicoletta has extensive experience leading all aspects of technical operations, including process and analytical development, manufacturing, supply chain, engineering and CMC lifecycle management. She joined Orchard Therapeutics from Novartis, where she held positions of increasing responsibility since 2004, most recently serving as global head of cell and gene therapies. In this role, Nicoletta led multidisciplinary international teams responsible for the end-to-end technical development, manufacturing and project management of several gene and cell therapies modalities, including lentiviral, adeno-associated virus (AAV), stem and CAR-T cell processes, from concept to commercialization. She also oversaw the integration of the CAR-T teams and AveXis’ AAV technical capabilities into Novartis’ technical R&D. Previously, Nicoletta was global head of technical development novel biologic entities and cell and gene therapies where she was responsible for the early phase development of biologics and gene therapies. Her broad industry experience encompasses global leadership in the development and manufacturing of sterile drug products and devices and approvals of several commercial assets.

A medicinal chemist by training, Nicoletta began her career in the biopharmaceutical industry as a formulation scientist at Pfizer. She earned her Ph.D. in pharmaceutical technologies from the University of Pavia in Italy. She is a registered pharmacist and member of the UK Royal and Italian Pharmaceutical societies.

member image alt text
Braden Parker
Chief Commercial Officer
Hematopoietic stem cell gene therapy continues to demonstrate great promise in treating diseases, such as neurodegenerative conditions, that have been historically difficult to address. It’s exciting to work on the cutting edge of medicine, building a commercial organization that aims to bring potentially curative therapies forward to patients in great need.

With more than 20 years of experience in the healthcare and biotech industry, Braden is a seasoned commercial leader with deep expertise in commercial strategy, operations, marketing, and market access. Braden joined Orchard Therapeutics in 2020 as the Senior Vice President and General Manager for North America. Since that time, Braden’s role has expanded to Chief Commercial Officer. In this capacity he is responsible for all commercial strategy and execution for the company, playing a critical role in shaping and achieving Orchard’s global growth strategy.

Prior to joining Orchard, Braden commercialized several rare oncolytic and genetic disorder products during his time at Celgene, NPS Pharma (acquired by Shire for $5.2B) and PTC Therapeutics, where he most recently served as the Vice President and General Manager for the U.S. In this role, Braden led the company’s first U.S. product launch in Duchenne muscular dystrophy and oversaw the strategic planning for their gene therapy business.

Braden received his M.B.A. from New York University Stern School of Business and a B.B.A. from the University of Notre Dame.

member image alt text
Frank Thomas
President & Chief Operating Officer
As a leader in gene therapy, I believe we should be providing innovative solutions across the continuum of a fully integrated company, all while turning groundbreaking innovation into transformative therapies for patients, supporting revolutionary ways to improve access to treatment, and driving long-term growth and value.

Frank brings nearly 20 years of experience in the biopharmaceutical industry as an accomplished financial and business executive, with a proven track record of success in leading operations and strategy, corporate finance and commercialization at publicly traded biotechnology companies. Frank joined Orchard in 2018 as chief financial officer. Since that time, his role has expanded to president and chief operating officer of Orchard. In this capacity, Frank creates and drives strategies for overall value-creation and long-term growth of the company. He currently oversees key functional areas for the business, including but not limited to, finance, commercial operations, corporate affairs and quality.

Frank previously served as president and chief operating officer of AMAG Pharmaceuticals (acquired in November 2020 by Covis Group), where he helped develop the business from a single product company in 2011 to one with a portfolio of commercial and development-stage products that generated more than $600 million in sales in 2017. During that time, Frank raised more than $1.8 billion in new capital to support AMAG’s growth strategy. Before joining AMAG, he served as chief operating officer and chief financial officer for Molecular Biometrics, Inc. Earlier in his career, Frank also served as chief executive officer for Critical Therapeutics and chief financial officer for Esperion Therapeutics. Each company completed its initial public offering in the U.S. during his tenure. Frank currently serves on the board of directors of Larimar Therapeutics and Spero Therapeutics.

Frank received his B.B.A. from the University of Michigan, Ann Arbor.

Board of Directors
Steven Altschuler, M.D.

Steven brings nearly 20 years of experience building and leading world-class, integrated, translational, value-based health care systems and transformational biotechnology companies. He currently serves as managing director of Healthcare Ventures at Ziff Capital Partners and was previously chair of the board of directors at Spark Therapeutics (acquired by Roche in 2019). In his role at Ziff Capital Partners, Dr. Altschuler co-leads the firm’s efforts toward investing in, and facilitating the start-up and development of, companies with potentially transformative technologies that emphasize cellular and molecular approaches to human disease. He previously co-founded Spark Therapeutics to develop and commercialize the preclinical and clinical gene therapy programs advanced at the Children’s Hospital of Philadelphia (CHOP) and other institutions. He served as Spark’s board chair from its founding through its acquisition in 2019, which included leading the company through a successful transition to a public company and the launch of an approved commercial product, which was the first gene therapy for an inherited disease approved by the U.S. Food and Drug Administration and European Medicines Agency. Dr. Altschuler formerly held chief executive positions at CHOP and University of Miami Health System. He is chairman of the board of directors of 89bio and a member of the board of directors of WW (formerly Weight Watchers International), AsclepiX Therapeutics, ImVaX and Platelet Biogenesis. He is also an independent trustee of the Brigham and Women’s Physician Organization at Mass General Brigham.

Dr. Altschuler holds a B.A. in mathematics and an M.D. from Case Western Reserve University.

Title of the wysi

The site uses cookies to provide you with a more responsive and personalized service. By using this site, you agree to our use of cookies as set out in our cookie policy.

Please read our privacy policy and cookie policy for more information on the cookies we use and how to delete or block the use of cookies.